The Use of Phage Display Technique for the Isolation of Androgen Receptor Interacting Peptides with (F/W)XXL(F/W) and FXXLY New Signature Motifs
Open accessThe DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
Early studies suggested that the signature motif, LXXLL, within steroid hormone receptor p160 coregulators may play important roles for the mediation of receptor-coregulator interaction. Interestingly, several androgen receptor (AR) coregulators, such as ARA70 and ARA55, may not use such a unique motif to mediate their coregulator activity. Here we apply the phage display technique to identify some new signature motifs, (F/W)XXL(F/W) and FXXLY (where F is phenylalanine, W is tryptophan, L is leucine, Y is tyrosine, and X is any amino acid) that can influence the interaction between AR and AR coregulators. Sequence analyses found that several AR coregulators, such as ARA70, ARA55, ARA54, and FHL2, contain FXXL(F/Y) motifs. Both glutathione S-transferase pull-down assays and transient transfection reporter assays demonstrate that these AR coregulators may use the FXXL(F/Y) motif to interact with AR and exert their AR coregulator activity. Exchanging the amino acid of Phe, Trp, or Tyr in this newly identified signature motif cluster may influence these peptides to interact with AR. The motif-containing peptides, as well as ARA70 or ARA54, may require selective flanking sequences for the better interaction with AR. In addition to influencing the AR transactivation, these motifs in AR-interacting peptides/proteins were also able to influence the AR N-/C-terminal interaction. Together, our data suggest that AR interacting peptides and/or AR coregulators may utilize the (F/W)XXL(F/W) and FXXLY motifs to mediate their interaction with AR and exert their influences on the AR transactivation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It prefers binding to the FXXLF sequence present in the NTD in contrast to what was seen with the ERα LBD (Dubbink et al., 2006; He et al., 2004; Hsu et al., 2003; Hur et al., 2004).”
From Structural Insights of Transcriptionally Active, Full-Length Androgen Receptor Coactivator Complexes (2020) · cites this paper as Hsu et al., 2003
Citations
Cites
Molecular basis of agonism and antagonism in the oestrogen receptor
Brzozowski, A. M., Pike, A. C. W., Dauter, Z., Hubbard, R. E., Bonn, T., Engström, O., Öhman, L., Greene, G. L., Gustafsson, J.-Å., & Carlquist, M. (1997) · Nature · doi:10.1038/39645 · Cited by 3,355
The Transcriptional Coactivators p300 and CBP Are Histone Acetyltransferases
Ogryzko, V. V., Schiltz, R. L., Russanova, V., Howard, B. H., & Nakatani, Y. (1996) · Cell · doi:10.1016/s0092-8674(00)82001-2 · Cited by 2,952
Sequence and Characterization of a Coactivator for the Steroid Hormone Receptor Superfamily
Oñate, S. A., Tsai, S. Y., Tsai, M.-J., & O'Malley, B. W. (1995) · Science · doi:10.1126/science.270.5240.1354 · Cited by 2,387
A signature motif in transcriptional co-activators mediates binding to nuclear receptors
Heery, D. M., Kalkhoven, E., Hoare, S., & Parker, M. G. (1997) · Nature · doi:10.1038/42750 · Cited by 2,128
Searching for Peptide Ligands with an Epitope Library
Scott, J. K., & Smith, G. P. (1990) · Science · doi:10.1126/science.1696028 · Cited by 2,084
Hörlein, A. J., Näär, A. M., Heinzel, T., Torchia, J., Gloss, B., Kurokawa, R., Ryan, A., Kamei, Y., Söderström, M., Glass, C. K., et al. (1995) · Nature · doi:10.1038/377397a0 · Cited by 2,034
Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ
Nolte, R. T., Wisely, G. B., Westin, S., Cobb, J. E., Lambert, M. H., Kurokawa, R., Rosenfeld, M. G., Willson, T. M., Glass, C. K., & Milburn, M. V. (1998) · Nature · doi:10.1038/25931 · Cited by 1,958
The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function
Torchia, J., Rose, D. W., Inostroza, J., Kamei, Y., Westin, S., Glass, C. K., & Rosenfeld, M. G. (1997) · Nature · doi:10.1038/42652 · Cited by 1,283
Steroid receptor coactivator-1 is a histone acetyltransferase
Spencer, T. E., Jenster, G., Burcin, M. M., Allis, C. D., Zhou, J., Mizzen, C. A., McKenna, N. J., Onate, S. A., Tsai, S. Y., Tsai, M.-J., et al. (1997) · Nature · doi:10.1038/38304 · Cited by 1,243
Nuclear Receptor Repression Mediated by a Complex Containing SMRT, mSin3A, and Histone Deacetylase
Nagy, L., Kao, H.-Y., Chakravarti, D., Lin, R. J., Hassig, C. A., Ayer, D. E., Schreiber, S. L., & Evans, R. M. (1997) · Cell · doi:10.1016/s0092-8674(00)80218-4 · Cited by 1,230
Research works printed but not linked: 7
- Beekman, 1993, Mol. Endocrinol., 7, 1266
- Parmley, 1989, Adv. Exp. Med. Biol., 251, 215
- Hall, 2000, Mol. Endocrinol., 14, 2010
- Chang, 2002, Mol. Endocrinol., 16, 647, 10.1210/mend.16.4.0818 · doi:10.1210/mend.16.4.0818 · Paper page
- Zhou, 2002, Mol. Endocrinol., 16, 287, 10.1210/mend.16.2.0765 · doi:10.1210/mend.16.2.0765 · Paper page
- Hsu, C., Yeh, S., and Chang, C. (2002) 84th Endocrine Society Annual Meeting, San Francisco, June 19–22, p. 527, Abstr. P3–144, The Endocrine Society Press, Bethesda, MD
- Santoro, 1994, Oncogene, 9, 509
Cited by
Heemers, H. V., & Tindall, D. J. (2007) · Endocrine Reviews · doi:10.1210/er.2007-0019 · Cited by 753
RBR E3 ubiquitin ligases: new structures, new insights, new questions
Spratt, D. E., Walden, H., & Shaw, G. S. (2014) · Biochemical Journal · doi:10.1042/bj20140006 · Cited by 315
He, B., Gampe, R. T., Kole, A. J., Hnat, A. T., Stanley, T. B., An, G., Stewart, E. L., Kalman, R. I., Minges, J. T., & Wilson, E. M. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.09.036 · Cited by 295
“AR AF2Duke University preferentially binds the FXXLF motif in the AR NH2-termi-Durham, North Carolina 27710 nal region (He et al., 2000) and AR coregulatory proteins (He et al., 2002b; Hsu et al., 2003).”
BackgroundRecognition and Accommodation at the Androgen Receptor Coactivator Binding Interface
Hur, E., Pfaff, S. J., Payne, E. S., Grøn, H., Buehrer, B. M., & Fletterick, R. J. (2004) · PLoS Biology · doi:10.1371/journal.pbio.0020274 · Cited by 234
“…used to study coactivator recognition specificity and to identify coactivator motif sequence variants preferred by the estrogen receptor (ER), thyroid hormone receptor (TR) b, and most recently AR (Chang et al. 1999; Norris et al. 1999; Paige et al. 1999; Northrop et al. 2000; Hsu et al. 2003).”
BackgroundResultInfluentialLavery, D. N., & Mcewan, I. J. (2005) · Biochemical Journal · doi:10.1042/bj20050872 · Cited by 227
Modulation of Androgen Receptor Activation Function 2 by Testosterone and Dihydrotestosterone
Askew, E. B., Gampe, R. T., Stanley, T. B., Faggart, J. L., & Wilson, E. M. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m703268200 · Cited by 210
From A to Z and back? Multicompartment proteins in the sarcomere
Lange, S., Ehler, E., & Gautel, M. (2006) · Trends in Cell Biology · doi:10.1016/j.tcb.2005.11.007 · Cited by 184
“Recent studies link FHL2 to several transcription factors and transcriptional co-activators or co-repressors, such as SRF [37], the hormone receptors androgen receptor (AR) [38, 39 ] and estrogen receptor [40], the cyclic AMP response element binding protein (CREB), the CREB-binding protein (CBP) and its homolog p300,…”
BackgroundNedelsky, N. B., Pennuto, M., Smith, R. B., Palazzolo, I., Moore, J., Nie, Z., Neale, G., & Taylor, J. P. (2010) · Neuron · doi:10.1016/j.neuron.2010.08.034 · Cited by 166
Structural Insights of Transcriptionally Active, Full-Length Androgen Receptor Coactivator Complexes
Yu, X., Yi, P., Hamilton, R. A., Shen, H., Chen, M., Foulds, C. E., Mancini, M. A., Ludtke, S. J., Wang, Z., & O’Malley, B. W. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.06.031 · Cited by 154
Centenera, M. M., Harris, J. M., Tilley, W. D., & Butler, L. M. (2008) · Molecular Endocrinology · doi:10.1210/me.2008-0017 · Cited by 145
He, B., Bai, S., Hnat, A. T., Kalman, R. I., Minges, J. T., Patterson, C., & Wilson, E. M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403117200 · Cited by 136
Androgen receptor coregulators: recruitment via the coactivator binding groove
van de Wijngaart, D. J., Dubbink, H. J., van Royen, M. E., Trapman, J., & Jenster, G. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.08.007 · Cited by 122
Distinct recognition modes of FXXLF and LXXLL motifs by the androgen receptor
Dubbink, H. J., Hersmus, R., Verma, C. S., van der Korput, H. A. G. M., Berrevoets, C. A., van Tol, J., Ziel-van der Made, A. C. J., Brinkmann, A. O., Pike, A. C. W., & Trapman, J. (2004) · Molecular Endocrinology · doi:10.1210/me.2003-0375 · Cited by 118
Structural and functional insights into nuclear receptor signaling
Jin, L., & Li, Y. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.08.007 · Cited by 112
“Instead, AR prefers to interact with the FXXLF motif presented in the N-terminal domains of many AR coactivators [48;49].”
BackgroundAndrogen Receptor Coregulators in Prostate Cancer
Rahman, M., Miyamoto, H., & Chang, C. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0746-3 · Cited by 102
Self-citationHu, Y.-C., Yeh, S., Yeh, S.-D., Sampson, E. R., Huang, J., Li, P., Hsu, C.-L., Ting, H.-J., Lin, H.-K., Wang, L., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m401781200 · Cited by 98
Self-citationProgesterone receptor modulators and the endometrium: changes and consequences†
Horne, F. M., & Blithe, D. (2007) · Human Reproduction Update · doi:10.1093/humupd/dmm023 · Cited by 98
“The use of phage display to identify potential AR cofactors (Hsu et al., 2003) may serve as a model for SPRM discovery.”
BackgroundDuff, J., & McEwan, I. J. (2005) · Molecular Endocrinology · doi:10.1210/me.2005-0231 · Cited by 92
“Unlike other members of the nuclear receptor superfamily, the AR exhibits little or no AF2 activity (50, 51) and shows preference for the motif FxxLF, present in the AR-NTD and some AR coactivator proteins, over the LxxLL motifs present in the p160 coactivator family (52, 53).”
BackgroundYang, Z., Chang, Y., Miyamoto, H., Ni, J., Niu, Y., Chen, Z.-D., Chen, Y., Yao, J. L., di Sant'Agnese, P. A., & Chang, C. (2006) · Molecular Endocrinology · doi:10.1210/me.2006-0104 · Cited by 84
“ARA54 Interacts with Transgelin in Vitro and in Vivo A, Mammalian two-hybrid assay: 3T3-L1 and COS-1 cells cultured in 24-well plate were cotransfected with 0.5 g pVP16, pM, pM-ARA54, pVP16-ARA54, pCMX-GAL4-AR, pCMX-VP16-AR, and pVP16-transgelin as indicated, together with 0.4 g pG5-LUC reporter plasmid and 0.5 ng p…”
InfluentialSelf-citationMcEwan, I. J., Lavery, D., Fischer, K., & Watt, K. (2007) · Nuclear Receptor Signaling · doi:10.1621/nrs.05001 · Cited by 81
Brooke, G. N., Parker, M. G., & Bevan, C. L. (2008) · Oncogene · doi:10.1038/sj.onc.1210955 · Cited by 79
“However, the AR is idiosyncratic in that it appears to interact preferentially with phenylalanine-rich motifs, found in several AR coactivators including ARA70, FHL2 and gelsolin (Hsu et al., 2003; Dubbink et al., 2004; Hur et al., 2004; van de Wijngaart et al., 2006).”
BackgroundInfluentialAndrogen receptor–cofactor interactions as targets for new drug discovery
Chang, C., & McDonnell, D. P. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.03.002 · Cited by 84
Self-citationPhage Display of Random Peptide Libraries: Applications, Limits, and Potential
Szardenings, M. (2003) · Journal of Receptors and Signal Transduction · doi:10.1081/rrs-120026973 · Cited by 76
Tran, M. K., Kurakula, K., Koenis, D. S., & de Vries, C. J. M. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.11.002 · Cited by 76
“[27] FHL2 enhances the transcriptional activity of AR, which in some cell types also involves FHL2 interaction with Proline, glutamate and leucine rich protein 1 (PELP1).”
BackgroundChang, C.-Y., Abdo, J., Hartney, T., & McDonnell, D. P. (2005) · Molecular Endocrinology · doi:10.1210/me.2005-0072 · Cited by 70
Self-citationHsu, C.-L., Chen, Y., Ting, H., Lin, W., Yang, Z., Zhang, Y., Wang, L., Wu, C., Chang, H., Yeh, S., et al. (2004) · Molecular Endocrinology · doi:10.1210/me.2004-0190 · Cited by 68
Self-citationCantin, L., Faucher, F., Couture, J., de Jesus-Tran, K. P., Legrand, P., Ciobanu, L. C., Fréchette, Y., Labrecque, R., Singh, S. M., Labrie, F., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m705524200 · Cited by 67
van de Wijngaart, D. J., van Royen, M. E., Hersmus, R., Pike, A. C. W., Houtsmuller, A. B., Jenster, G., Trapman, J., & Dubbink, H. J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602567200 · Cited by 66
Beyond the Ligand-Binding Pocket: Targeting Alternate Sites in Nuclear Receptors
Caboni, L., & Lloyd, D. G. (2012) · Medicinal Research Reviews · doi:10.1002/med.21275 · Cited by 67
Designing scaffolds of peptides for phage display libraries
Uchiyama, F., Tanaka, Y., Minari, Y., & Tokui, N. (2005) · Journal of Bioscience and Bioengineering · doi:10.1263/jbb.99.448 · Cited by 64
Bai, S., & Wilson, E. M. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01672-07 · Cited by 63
“However, these same AF2 site mutations that disrupt AR FXXLF motif binding also inhibit AR AF2 recruitment of SRC/p160 coactivator LXXLL motifs, which bind with at least 5- to 10-fold-lower affinity than the FXXLF motifs present in AR (22, 23), putative AR coregulators (27, 32, 58), and peptides identified in peptide…”
BackgroundHsu, C.-L., Liu, J.-S., Wu, P.-L., Guan, H., Chen, Y., Lin, A.-C., Ting, H., Pang, S., Yeh, S.-D., Ma, W., et al. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.06.009 · Cited by 58
“In fact, the FxxLF-likemotif exists in many AR coregulators and plays an important role in modulating coregulator-mediated AR functions (Heinlein and Chang, 2002; Hsu et al., 2003; Yeh and Chang, 1996).”
BackgroundMethodInfluentialSelf-citationQuigley, C. A., Tan, J.-A., He, B., Zhou, Z.-X., Mébarki, F., Morel, Y., Forest, M. G., Chatelain, P., Ritzén, E. M., French, F. S., et al. (2004) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2004.08.007 · Cited by 63
Recapitulation and Design of Protein Binding Peptide Structures and Sequences
Sood, V. D., & Baker, D. A. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2006.01.045 · Cited by 59
“31 We tested the ability of our protocol to predict the specific cofactors for the AR and the ER, starting from co-crystal structures 1XOW 32 and 3ERD, 33 respectively.”
MethodKollara, A., & Brown, T. J. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1000-y · Cited by 58
“amino acids flanking the FXXLF motif are also important for the functional interaction with AR [26, 29].”
BackgroundMethodWang, L., Hsu, C.-L., Ni, J., Wang, P.-H., Yeh, S., Keng, P., & Chang, C. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.5.2202-2213.2004 · Cited by 54
“is a ligand-dependent AR-associated peptide motif (33).”
Self-citationCoregulator control of androgen receptor action by a novel nuclear receptor-binding motif
Jehle, K., Cato, L., Neeb, A., Muhle-Goll, C., Jung, N., Smith, E. W., Buzon, V., Carbó, L. R., Estébanez-Perpiñá, E., Schmitz, K., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.534859 · Cited by 53
“Previous studies to identify sequences on coactivators that bind the LBD of nuclear receptors using phage display libraries have only identified variants of the LXXLL motif (11, 47).”
BackgroundInfluentialSelf-citationYang, J., Chang, C.-Y., Safi, R., Morgan, J., McDonnell, D. P., Fuller, P. J., Clyne, C. D., & Young, M. J. (2011) · Molecular Endocrinology · doi:10.1210/me.2010-0193 · Cited by 53
Self-citationAskew, E. B., Bai, S., Blackwelder, A. J., & Wilson, E. M. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.120600 · Cited by 52
Minoxidil may suppress androgen receptor-related functions
Hsu, C., Liu, J.-S., Lin, A.-C., Yang, C.-H., Chung, W., & Wu, W. (2014) · Oncotarget · doi:10.18632/oncotarget.1886 · Cited by 56
“Protein expression and purification were as described previously [23].”
MethodSelf-citationvan de Wijngaart, D. J., Dubbink, H. J., Molier, M., de Vos, C., Trapman, J., & Jenster, G. W. (2009) · Molecular Endocrinology · doi:10.1210/me.2008-0280 · Cited by 55
“Previous screenings for novel AR-interacting motifs already demonstrated that W (Trp) residues could be compatible with binding to the AR coactivator binding groove when present at positions 1 and 5 (21, 25, 43).”
Dubbink, H. J., Hersmus, R., Pike, A. C. W., Molier, M., Brinkmann, A. O., Jenster, G., & Trapman, J. (2006) · Molecular Endocrinology · doi:10.1210/me.2005-0348 · Cited by 47
Shiota, M., Yokomizo, A., Fujimoto, N., & Naito, S. (2011) · Current Cancer Drug Targets · doi:10.2174/156800911796798904 · Cited by 49
“In the AR, AF-2 binds preferentially to FXXLF-motifs, including the 23-FQNLF-27 found in AR NTD [19–22], leading to N/C interaction and AR activation.”
BackgroundBai, S., Grossman, G., Yuan, L., Lessey, B. A., French, F. S., Young, S. L., & Wilson, E. M. (2007) · Molecular Human Reproduction · doi:10.1093/molehr/gam080 · Cited by 49
“SRC/p160 coactivator LXXLL motifs and FXXLF motifs in putative AR coregulators (He et al., 2002; Hsu et al., 2003).”
BackgroundTing, H., Bao, B., Hsu, C., & Lee, Y. (2005) · Endocrine · doi:10.1385/endo:26:1:001 · Cited by 43
Self-citationThe Sarcomere and the Nucleus: Functional Links to Hypertrophy, Atrophy and Sarcopenia
Gautel, M. (2008) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-84847-1_13 · Cited by 45
Analysis of Interdomain Interactions of the Androgen Receptor
Wilson, E. M. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-243-4_8 · Cited by 42
Structural features discriminate androgen receptor N/C terminal and coactivator interactions
Askew, E. B., Minges, J. T., Hnat, A. T., & Wilson, E. M. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.03.026 · Cited by 40
“Other AR coactivators compete with the AR N/C interaction by binding AF2 through their own FXXLF (He et al., 2002b; Hsu et al., 2003) or FXXLF-related motif (van de Wijngaart et al.”
BackgroundSteroid receptor/coactivator binding inhibitors: An update
Skowron, K. J., Booker, K., Cheng, C., Creed, S. M., David, B. P., Lazzara, P. R., Lian, A., Siddiqui, Z., Speltz, T. E., & Moore, T. W. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.110471 · Cited by 39
“The first CBIs reported for AR were peptides containing a modified NR box motif (F/W)XXL(F/W) mimicking the LXXLL motif, common to most steroid-receptor coactivator proteins (He et al., 2002; Hsu et al., 2003).”
BackgroundWang, L., Wu, C., Zheng, Y., Qiu, X., Wang, L., Fan, H., Han, W., Lv, B., Wang, Y., Zhu, X., et al. (2004) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2003.11.017 · Cited by 34
Pearce, K. H., Iannone, M. A., Simmons, C. A., & Gray, J. G. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03201-5 · Cited by 39
Yang, Z., Chang, Y., Miyamoto, H., Yeh, S., Yao, J. L., di Sant'Agnese, P. A., Tsai, M.-Y., & Chang, C. (2006) · Endocrinology · doi:10.1210/en.2006-0716 · Cited by 27
“pGEX-GSTARA54 was constructed as described previously (37).”
Self-citationBiron, É., & Bédard, F. (2015) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2015.07.006 · Cited by 28
Klein, F. A. C., Atkinson, R. A., Potier, N., Moras, D., & Cavarelli, J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m411697200 · Cited by 24
Ting, H., & Chang, C. (2008) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2008.06.001 · Cited by 25
Self-citationFiandalo, M. V., Wu, W., & Mohler, J. L. (2013) · Current Drug Targets · doi:10.2174/1389450111314040004 · Cited by 20
“NRs associate with the LXXLLs of co-activator proteins via AF-2 and lead to NR transcriptional activation [89-92].”
BackgroundInfluentialMuscle-Bound? A Tissue-Selective Nonsteroidal Androgen Receptor Modulator
Wilson, E. M. (2006) · Endocrinology · doi:10.1210/en.2006-1368 · Cited by 18
“site for FXXLF and WXXLF motifs present in AR that mediate the AR NH2- and carboxylterminal N/C interaction (13–16), FXXLF motifs in coregulatory proteins (17, 18), and as yet”
BackgroundAndrogens as the “old age stick” in skeletal muscle
Gentile, G., Stefano, F. D., Sorrentino, C., D’Angiolo, R., Lauretta, C., Giovannelli, P., Migliaccio, A., Castoria, G., & Donato, M. D. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02163-6 · Cited by 20
“The hydrogen per-oxide-inducible clone-5 (Hic-5), AR co-activator Hic-5 (ARA55) and paxillin (PXN) share similarities and serve as AR coactivators [52–54].”
Folkertsma, S., van Noort, P. I., de Heer, A., Carati, P., Brandt, R., Visser, A., Vriend, G., & de Vlieg, J. (2006) · Molecular Endocrinology · doi:10.1210/me.2006-0072 · Cited by 15
Androgen receptor inhibitors in treating prostate cancer
Cole, R. N., Fang, Q., Matsuoka, K., & Wang, Z. (2024) · Asian Journal of Andrology · doi:10.4103/aja202494 · Cited by 15
van de Wijngaart, D. J., Dubbink, H. J., Molier, M., de Vos, C., Jenster, G. W., & Trapman, J. (2010) · The Prostate · doi:10.1002/pros.21238 · Cited by 13
“Peptides containing FxxLF-like motifs have been demonstrated to block activities of AR [30,39,64].”
BackgroundBerntzen, G., Andersen, J. T., Ustgård-Andersen, K., Michaelsen, T. E., Mousavi, S. A., Qian, J. D., Kristiansen, P. E., Lauvrak, V., & Sandlie, I. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m803584200 · Cited by 10
Multiple functions and essential roles of nuclear receptor coactivators of bHLH-PAS family
Pecenova, L., & Farkas, R. (2016) · Endocrine Regulations · doi:10.1515/enr-2016-0019 · Cited by 10
“…more co-activators have been reported, including the SRC-1 related proteins, TIF2 and GRIP1, and other putative and unrelated co-activators, such as ARA70, Trip1, RIP140, and TIF1 (Nagy et al. 1999; Hsu et al. 2003; van de Wijngaart et al. 2006, 2012; Dasgupta et al. 2014; Stashi et al. 2014).”
BackgroundFunctional Motifs of the Androgen Receptor
Wilson, E. M. (2009) · Springer eBooks · doi:10.1007/978-0-387-69179-4_11 · Cited by 8
“Peptide display screens using the AR LBD as bait have detected a variety of FXXLF-related motifs, but few if any LXXLL motif-containing peptides (Chang et al. 2005; Hsu et al. 2003; van de Wijngaart et al. 2006).”
BackgroundBonagura, T. W., Deng, M., & Brown, T. R. (2006) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2006.08.012 · Cited by 8
A novel Arnt-interacting protein Ainp2 enhances the aryl hydrocarbon receptor signaling
Li, Y., Luu, T. C., & Chan, W. K. (2005) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2005.06.026 · Cited by 6
Hsu, C.-L., Liu, J.-S., Lin, T.-W., Chang, Y.-H., Kuo, Y., Lin, A.-C., Ting, H., Pang, S., Lee, L., Ma, W., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17843 · Cited by 6
“The assay procedures were performed as described previously [8].”
MethodSelf-citationEvolution of Melanoma Antigen-A11 (MAGEA11) During Primate Phylogeny
Willett, C. S., & Wilson, E. M. (2018) · Journal of Molecular Evolution · doi:10.1007/s00239-018-9838-8 · Cited by 6
Sigal, M., Egner, M., Okada, C., Merk, D., Sengoku, T., Katoh, T., & Suga, H. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c13803 · Cited by 8
The Androgen Receptor Coactivator-Binding Interface
Estébanez‐Perpiñá, E., & Fletterick, R. J. (2009) · Springer eBooks · doi:10.1007/978-0-387-69179-4_13 · Cited by 4
“Peptides identified by phage display contain hydrophobic sequences with homologous motifs have also been reported: FxxLF, FxxFF, FxxYF, FxxLW, WxxLF, WxxVW, and LxxLL (Y and W are tyrosine and tryptophan, respectively) (Hur et al. 2004; Hsu et al. 2003).”
BackgroundHuman CMTM2/CKLFSF2 enhances the ligand-induced transactivation of the androgen receptor
Liu, D., Yin, C., Zhang, Y., Tian, L., Li, T., Li, D., Ma, D., Guo, Y., & Wang, Y. (2009) · 中国科学通报:英文版 · doi:10.1007/s11434-009-0092-8 · Cited by 3
Targeting the Nuclear Receptor–Cofactor Interaction
Vaz, B., Möcklinghoff, S., & Brunsveld, L. (2008) · Methods and principles in medicinal chemistry · doi:10.1002/9783527623297.ch2 · Cited by 4
Structural basis for computational screening of non-steroidal androgen receptor ligands
Nyrönen, T., & Söderholm, A. A. (2009) · Expert Opinion on Drug Discovery · doi:10.1517/17460440903468680 · Cited by 2
“Instead, the AF2 of AR prefers binding of phenylalanine-rich FXXLF motifs that are found within the AR NTD and in a subset of AR interacting CoAs [106-109] .”
BackgroundWang, S., Ekoue, D. N., Raj, G. V., & Kittler, R. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.09.010 · Cited by 2
Song, T.-Q., & Li, J. (2019) · Current Computer - Aided Drug Design · doi:10.2174/1573409915666190502153307 · Cited by 2
“The corresponding experimental results indicate that BUD31 can block AR transcriptional activity, the AR N-C interaction and AR-mediated cancer cell growth [18-21].”
Wilson, E. M. (2015) · Springer eBooks · doi:10.1007/978-3-319-18729-7_8 · Cited by 1
Jamshidi, M., Keshavarzi, F., Amini, S., Laher, I., Gheysarzadeh, A., & Davari, K. (2023) · Cancer Reports · doi:10.1002/cnr2.1922 · Cited by 1
“However, Hsu et al. reported that the peptide inhibited AR transactivation, 26 while Chen et al. reported that AR transactivation recruits c-Jun and induces mitotic activation to increase proliferation.”
BackgroundTrapman, J. (2009) · Springer eBooks · doi:10.1007/978-0-387-69179-4_16 · Cited by 1
“Phage display has been used to select randomly for interacting peptide sequences with high affinity for the AR LBD ( Hsu et al. 2003; Hur et al. 2004; Chang et al. 2005).”
MethodReptides and Proteins Interacting with the Androgen Receptor
van de Wijngaart, D. J. (2009)
Modulation of Androgen Receptor Transcriptional Activity
Wong, H. Y. (2009) · RePub (Erasmus University Rotterdam) · Cited by 1
Targeting alpha-helix based protein interactions; nuclear receptors as a case study
Milroy, L. ‐., Nieto, L., & Brunsveld, L. (2012) · Royal Society of Chemistry eBooks · doi:10.1039/9781849734677-00238 · Cited by 1
Molecular mechanisms of androgen receptor functions
Steketee, K. (2007) · EUR Research Repository (Erasmus University Rotterdam) · Cited by 1
Lin, C., Huang, C.-Y., Lui, K., Chao, Y., Yeh, C., Lee, L.-Y., Huang, Y., Yang, Z., Hsieh, C., Fan, H.-C., et al. (2026) · Translational Oncology · doi:10.1016/j.tranon.2026.102670
“A dual luciferase reporter assay system (Promega) was used to measure the luciferase activity [28].”
Self-citationA Novel SXXLF Motif in the FXR N‐Terminal Domain Mediates Coregulator and Interdomain Interactions
Villalona, P., Pulahinge, T., Yu, T., Wenning, J. A., Khan, S. H., Frisbie, C. J., Magafas, J., Barbe, A., & Okafor, C. D. (2026) · ChemBioChem · doi:10.1002/cbic.202500967
“In particular, SENLF is similar to FQNLF in the NTD of the AR, found to participate in agonist-dependent LBD/AF-2 interactions [28, 35, 36, 39 – 41].”
Impact of a Novel Dehydroepiandrosterone Derivative on the Metabolism of RWPE-1 and LNCaP Cell Lines
Cabeza, M., Mejía, K., Heuze, Y., Morales-Pacheco, M., & Rodríguez‐Dorantes, M. (2026) · Oriental Journal Of Chemistry · doi:10.13005/ojc/420336
BindingDB (2017) · UC San Diego · doi:10.7270/q2qz28tm
Metadata
- Authors
- Hsu, C.-L., Chen, Y.-L., Yeh, S., Ting, H.-J., Hu, Y.-C., Lin, H., Wang, X., & Chang, C.
- Affiliations
- University of Rochester Medicine (US)
- Corresponding author
- Chang, Chawnshang
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2003-06
- Volume
- 278
- Issue
- 26
- Pages
- 23691-23698
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2172132882
- Cited by
- 85
- References
- 62
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 1 · 2023: 1 · 2020: 1 · 2019: 2 · 2018: 2 · 2017: 1 · 2016: 1 · 2015: 3 · 2014: 4 · 2013: 1 · 2012: 3
- FWCI
- 7.87
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6340 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (DK 60948, R01DK060948, R01DK060905, DK60905)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- androgen receptor, coregulators, FHL2, signature motifs, LXXLL motif, phage display, peptide isolation, transcriptional activation, steroid hormone receptors
- MeSH terms
- Amino Acid Sequence, Binding Sites, Carrier Proteins, Humans, Muscle Proteins, Peptide Fragments, Protein Binding, Receptors, Androgen, Transcription Factors, Oncogene Proteins, Trans-Activators, Homeodomain Proteins, Peptide Library, Amino Acid Motifs, Intracellular Signaling Peptides and Proteins, Nuclear Receptor Coactivators, LIM Domain Proteins, LIM-Homeodomain Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.